Vasopeptidase inhibitors: An emerging class of cardiovascular drugs

Hospital Pharmacist

Volumn 8, Issue 10, 2001, Pages 280-282

  Sani, Morgan ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; OMAPATRILAT; PLACEBO; VASOPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME INHIBITION; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035204174     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Omapatrilat does not affect the steady state of warfarin
2. Effects of BMS-186716, a new dual metallo-protease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and ACE activity in healthy men
3. Omapatrilat is not a diuretic: Single and multiple dose analysis of the urinary excretion of sodium
4. The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat. A pilot study
5. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor
6. Randomised double-blind comparison of omapatrilat with amlodipine in mild to moderate hypertension
7. Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring
8. Omapatrilat versus losartan in hypertensive patients with LV hypertrophy
9. Omapatrilat, a vasopeptidase inhibitor, is an effective antihypertensive agent in mild to moderate hypertension
10. Vasopeptidase inhibition and angioedema
11. The effect of vasopeptidase inhibition by omapatrilat in salt-sensitive hypertensives
12. Renal characteristics of omapatrilat in saltsensitive hypertensive patients
13. Efficacy and safety of omapatrilat in subjects with isolated systolic hypertension
14. The safety and efficacy of omapatrilat in patients with hypertension and renal insufficiency
15. Comparison of vasopeptidase inhibitors, omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
16. Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: Evidence from the omapatrilat heart failure programme
17. The clinical, cardiac, renal arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
18. Omapatrilat in persons with enhance risk of atherosclerotic events: The OPERA trial